ArticleScientific reports2026
Prognostic impact of renal microcirculatory dysfunction in heart failure assessed by superb microvascular imaging.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
The critical role of cardio-renal interactions in heart failure (HF) prognosis has gained increasing recognition, yet standardized methods for their assessment remain elusive. This study introduces a novel approach utilizing Superb Microvascular Imaging (SMI), an advanced ultrasound technique enabling detailed microvascular flow visualization, to evaluate renal microcirculation. We conducted a retrospective analysis of 78 patients who underwent renal ultrasonography with SMI between October 2020 and May 2023. Temporal changes in the Vascular Index (VI), which quantifies the blood flow signal area within the region of interest on SMI images, were measured. Key parameters included Maximum VI (Max.VI), Minimum VI (Min.VI), and the cyclic variation of VI, calculated as the intrarenal perfusion index (IRPI) = (Max.VI - Min.VI) / Max.VI within one cardiac cycle. The primary endpoint was a composite event (CE), defined as all-cause mortality or unplanned hospitalization due to worsening HF. Over a mean follow-up period of 1.6 ± 0.8 years, 13 of 78 patients (17%) experienced CEs. Patients with CEs exhibited significantly lower Max.VI and Min.VI values, while IRPI was significantly elevated in this group compared to those without CEs. Univariable Cox regression analyses revealed significant associations between Max.VI, Min.VI, and IRPI with CEs. In multivariable Cox regression analyses, Max.VI and Min.VI maintained significant associations with CEs after adjusting for creatinine, estimated central venous pressure, and intra-renal venous flow pattern. Kaplan-Meier analysis demonstrated that Max.VI (< 0.31, as determined by ROC analysis; 43% vs. 7%, log-rank p < 0.001), Min.VI (< 0.08, 42% vs. 8%, log-rank p < 0.001), and IRPI (> 0.70, 39% vs. 10%, log-rank p = 0.002) could effectively stratify CE prognosis. This novel application of SMI for renal circulation assessment provides valuable insights into HF prognosis and enables risk stratification beyond conventional markers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.